Director of Molecular Diagnostics
- Honorary Consultant Haematologist
The aim of our research is to identify molecular-based disease classifiers using clinical omics to underpin precision medicine approaches to be used for the selection of patients for the appropriate therapy.
Professor Schuh has participated as a principle or chief investigator in over 30 early or late phase clinical trials in chronic lymphocytic leukaemia. A number of these led to subsequent NICE approvals and have changed clinical practice in the UK and worldwide. As the Director of the Oxford NIHR Molecular Diagnostics Centre (MDC), she receives grants from the NIHR, Wellcome Trust, Technology Strategy Board and Bloodwise.
Her primary research interest is with the development, evaluation and implementation of new technologies for precision diagnostics with a particular focus on genomics. She leads the Genomics England Clinical Interpretation Partnership for Haematological Malignancies on behalf of the NCRN clinical investigators and has authored or co-authored over 80 peer-reviewed publications in the last five years.
Mato AR. et al, (2019), Blood Adv, 3, 1568 - 1573
Appleby N. et al, (2019), BMC Cancer, 19
Awan FT. et al, (2019), Blood Adv, 3, 1553 - 1562
Chronic Lymphocytic Leukemia
Hallek M. et al, (2019)
Roeker LE. et al, (2019), Clin Cancer Res